Publications by authors named "M Elangovan"

Cotton leaf curl disease (CLCuD) is a major constraint for production of cotton (Gossypium sp.) in Northwest India. CLCuD is caused by a monopartite, circular ssDNA virus belonging to the genus Begomovirus in association with betasatellites and alphasatellites, and ttransmitted by a whitefly vector (Bemisia tabaci).

View Article and Find Full Text PDF

The disease amyloid plaques, neurofibrillary tangles, synaptic dysfunction, and neuronal death gradually accumulate throughout Alzheimer's disease (AD), resulting in cognitive decline and functional disability. The challenges of dataset quality, interpretability, ethical integration, population variety, and picture standardization must be addressed using deep learning for the functional magnetic resonance imaging (MRI) classification of AD in order to guarantee a trustworthy and practical therapeutic application. In this manuscript Classifying AD using a finite basis physics neural network (CAD-FBPINN) is proposed.

View Article and Find Full Text PDF

In therapeutic diagnostics, early diagnosis and monitoring of heart disease is dependent on fast time-series MRI data processing. Robust encryption techniques are necessary to guarantee patient confidentiality. While deep learning (DL) algorithm have improved medical imaging, privacy and performance are still hard to balance.

View Article and Find Full Text PDF

Excessive accumulation of amyloid-β (Aβ) has been associated with the pathogenesis of Alzheimer's disease (AD). Clinical studies have further proven that elimination of Aβ can be a viable therapeutic option. In the current study, we conceptualized a fusion membrane protein, referred to as synthetic α-secretase (SAS), that can cleave amyloid precursor protein (APP) and Aβ specifically at the α-site.

View Article and Find Full Text PDF
Article Synopsis
  • * The study discovered that anti-VEGF drugs like bevacizumab, ranibizumab, and aflibercept promote epithelial-mesenchymal transition (EMT) in retinal cells, increasing the levels of CCN2, a pro-fibrotic factor.
  • * Co-treatment with CCN5, which inhibits CCN2, mitigated the negative effects of anti-VEGF drugs, indicating that targeting these pathways could improve treatment outcomes for nAMD.
View Article and Find Full Text PDF